Cargando…
Recent advances and application of PD-1 blockade in sarcoma
The role of the programmed death-1 (PD-1) signaling pathway in tumor immunotherapy is becoming increasingly important, and several PD-1-blocking agents have been approved by the US Food and Drug Administration. PD-1-blocking therapy alone or in combination with other therapeutic modalities has becom...
Autores principales: | Zuo, Wenli, Zhao, Lingdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711553/ https://www.ncbi.nlm.nih.gov/pubmed/31692518 http://dx.doi.org/10.2147/OTT.S220045 |
Ejemplares similares
-
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021) -
Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report
por: Imataki, Osamu, et al.
Publicado: (2022) -
Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019) -
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022) -
Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)